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1. Introduction
A major factor which determines the overall success of a pharmaceutical product is the solid-
state form in which the active pharmaceutical compound exists. It is a well-known fact that
most pharmaceuticals possess the ability to exist in different solid forms. The solid-state of a
compound significantly influences the physical-, chemical and mechanical properties exhib‐
ited by the drug [1, 2]. Subsequently, these properties not only affect the processability and
stability of a drug, but also the dissolution and bioavailability thereof [3]. Optimal drug
performance depends to a large extent on the solid-state form used in the design and devel‐
opment of a pharmaceutical product. Considering the abovementioned facts it becomes quite
evident why it is so important to select the best solid-state form of a given drug to be incor‐
porated into a dosage form. Not only is it imperative that the appropriate solid-state form is
chosen, but also to ensure that the specific form will remain unchanged during processing,
manufacturing as well as during distribution and storage of the final product [4]. Knowledge
of solid-state forms of drugs and the identification of possible transformations have developed
from mere scientific interest to matters that must be addressed for every dosage form.
Usually, the most stable solid-state form of a given drug is preferred for incorporation into
marketable formulations, because a metastable form may transform to its stable counterpart.
Such a transformation may lead to precipitation from solution, physical instability of the
dosage form and even changes, and resultant unpredictability, in the bioavailability thereof
[5]. Whilst the most stable solid-state forms of drugs offer the best shelf-life for products, they
are also always the least soluble forms. This is the reason why there is now a heightened interest
in the use of metastable solid-state forms such as metastable polymorphs, amorphous drugs
and amorphous solid dispersions, in pharmaceutical products. A decade ago the incorporation
of metastable forms in dosage forms was almost unthinkable and a contradiction of pharma‐
ceutical manufacturing guidelines, but it is steadily becoming more commonplace. The
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challenge facing pharmaceutical researchers is understanding and preventing/managing the
tendency of these metastable forms to invariably revert to their most thermodynamically stable
solid-state form, either during processing, storage, distribution or patient administration [3].
Transformations often result from the interaction of a drug with a solvent. These transforma‐
tions are usually classified as: solvent-mediated, solution-mediated or solvent-exchange
processes. A review of current literature quickly shows that these terms, especially the first
two, are often used interchangeably and that many authors have different views on which
process is involved in a given transformation. It is evident that the different solvent-interactive
processes need to be defined more clearly and, by reverting to fundamental principles, this
chapter aims to do just that.
2. Overview of solid-state transformations
A solid-state transformation may be defined as any transition from one solid-state form of a
compound to another solid-state form resulting in the same composition but different packing
arrangement. The phenomena that govern solid-state transformations can be classified as
thermodynamic, kinetic and molecular recognition. Competition or reinforcement between
these processes is affected by mechanical, thermal and chemical stresses. Molecular recogni‐
tion determines the number of possible solid-states for any given molecular entity. Thermo‐
dynamics control the relative stability and the conditions/direction in which a transformation
can occur, but kinetics determines how long a transformation will take [6, 7, 8]. The transfor‐
mations that may occur in drugs are classified in accordance to the general underlying
process(es) of the transformation(s). The following are listed by Zhang et al. [4]: solid-solid,
solvent-mediated and solution-mediated. All solid-state transformation types will not be
discussed in this chapter but for the sake of completeness and to serve as a quick reference
guide, Table 1 summarises solid-state transformations, as described in literature, in terms of
the type of transformation, possible underlying process(es) as well as processing steps that
might induce each transformation. The next few paragraphs will briefly discuss all solid-state
transformations. Special attention will be paid to the transitions involving solvent-interactive
transformations and these will be discussed in more detail throughout the chapter.
Solid-solid transformations occur as a direct conversion from one solid-state form to another
without an intermediate solution or melt phase. Melt-induced transformation occurs when a
solid-state form of a drug is melted and subsequently cooled. Parameters such as the cooling
rate, nucleation rate and the presence of impurities or seed crystals determine the solid-state
form that will be produced. In such a solid-melt-solid process, both the initial form and the
resultant form can be either crystalline or amorphous [4]. Solution-mediated and solvent-
mediated transformations are typically respectively described only as occurring in solution or
in the presence of a solvent (or solvent vapour). Two important facts that should be highlighted
here is that almost any environment or processing method can initiate a solid-state transfor‐
mation and also that it can be extremely difficult to identify the causative agent or process.
The study and proper understanding of the types of solid-state transformations is currently
seen as imperative within the pharmaceutical industry. Recently more and more attention is
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being paid to the identification of solid-state transitions of drugs and excipients. As mentioned
earlier, the physical state in which an active pharmaceutical ingredient (API) exists is deter‐
minant towards the stability, processability, solubility and bioavailability of the compound [2].
Transformation studies of pharmaceutical compounds will assist in the identification of the
type of solid-state transformation that occurs, which in turn will help to identify the mechanism
of the transformation process and most importantly the processing step responsible for the
transformation. Information obtained through transformation studies will allow pharmaceut‐
ical scientists to make appropriate, cost-effective and time saving decisions throughout the
manufacturing process of a pharmaceutical product.
Transformation type Transformation result Transformation process Possible processing step involved
Solvation or hydration
• Transformation of an
anhydrous crystalline form
to a solvate or hydrate
• Solution-mediated
• Solvent-mediated
• Crystallisation
• Wet granulation
• Pelletisation
• Exposure to humidity/moisture during
manufacturing or storage
Desolvation or
dehydration
• Solvate/hydrate to
amorphous form
• Solvate/hydrate to
anhydrous crystalline form
• Solid-solid
• Exposure to dry conditions during
manufacturing or storage
• Processing steps involving the drying of
the drug i.e. spray-drying, freeze-drying or
fluid-bed drying
Polymorphic
transformation
• Polymorphic form X to
polymorphic form Y of a
drug
• Solid-solid
• Solution-mediated
• Solid-melt-solid
• Grinding/milling
• Compression
• Heating
• Recrystallisation
• Heating above melting point, followed
by cooling
• Dissolution or solubility testing of
metastable forms
Vitrification
• Crystalline form to
amorphous form
• Solvate/hydrate to
amorphous form
• Solid-solid
• Solid-melt-solid
• Milling
• Compression
• Dehydration of solvates/hydrates
• Spray-drying
• Freeze-drying
• Quench cooling of the melt
Crystallisation • Amorphous form tocrystalline form
• Solution-mediated
• Solid-solid
• Heating
• Grinding/milling
• Humidity or plasticiser-induced
crystallisation
• Dissolution or solubility testing of
amorphous drugs
Table 1. Summary of solid-state transformations of drugs [4, 9]
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The unintentional transformation of a solid form to another is an unwanted occurrence within
the pharmaceutical industry. If necessary preventative steps aren’t put in place, a multitude
of unplanned solid-state transitions can occur throughout the manufacturing and processing
cycle of a pharmaceutical compound, leading to unexpected and unwanted product proper‐
ties. One unintended transition can lead to an array of problems that detrimentally affect
further processing and development steps. Solid-state transformations may also be advanta‐
geous, if they are utilised in a controlled and conscious manner to deliberately obtain alternate
solid-state forms.
3. Solvent-interactive transformations
Within the context of solid-state transformations, we propose the use of “solvent-interactive
transformations” as a collective term for all transformations that are caused or accelerated by
the presence of solvent. One often sees the two terms, solvent- or solution-mediated transfor‐
mations, used interchangeably by many authors when, in fact, they are very different proc‐
esses. The synonymous use of these two terms can be attributed to a lack of proper
understanding of the different pathways that the two transformations follow. This section aims
to explain the subtle but extremely significant differences between solvent- and solution-
mediated transformations, as well as to put forth a new concept namely “solvent-catalysed
transformation”.
In an effort to obtain sufficient information to clarify the discrepancies that exist with the
current use of the terms solvent- and solution-mediated, a literature study was undertaken.
Table 2 provides a summary of some of the misconceptions and overly generalised statements
found in literature.
Solvent-mediated transformation Solution-mediated transformation
- Always: Metastable form → Stable form
Driving force is the removal of solvent from the system -
Transformation occurs during drying/removal of solvent Transformation occurs when metastable form is in contact
with the saturated solution of the drug
Transition occur out of solvent Transition occurs in solvent
Table 2. Summary of some of the misconceptions and overly generalised statements regarding solvent- and solution-
mediated transformations, as currently found in literature [4, 5, 9, 10, 11]
Our attempts to extract, from literature, concrete facts and unambiguous definitions that could
be applied to explain the difference between solvent- and solution-mediated transformation,
has met mostly with failure. To make sense of all the contradictory information that is available
in current texts, we have opted for a fresh start in defining the relevant terms based on
fundamentals. The first question that needs to be answered is: What does “mediation” mean in
scientific context?
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Mediate: “Exhibiting indirect causation, connection, or relation” [12] or “Connected indirectly
through another person or thing” [13]. From these definitions it is clear that only those solvent-
interactive transformations in which the initial solid form does not directly transform to a
second solid form may be described as being either solvent- or solution-mediated.
Mediation may be further elaborated upon by employing, in its most simple form, the concept
of a statistical mediation model (Figure 1) [14]. According to such a model, the initial solid
form (Form X) is the independent variable, because it is the starting material and its existence
is independent of both the transformation itself (B) and the product of transformation (Form
Y). In a mediated process, there is no direct causal relationship (C) between the independent
variable (starting material) and the dependent variable (product of the transformation).
Instead, the relationship between the independent variable and the dependent variable is
governed by a mediator variable, which in this case is either a solution or a solid-solvent
association.
The product of a mediated transformation may be either more or less stable than the starting
material. Dissolution testing of a metastable starting material may cause solution-mediated
transformation to a more stable form, but recrystallisation techniques may also be used to
produce metastable forms of a stable starting material via solution-mediated transformation.
It is important to keep in mind that this chapter focusses on but one variable, the role of
solvents, but in real-world applications the outcome of a mediated transformation will be
dependent on numerous thermodynamic and kinetic variables [6].
Many solid-solid transformations are capable, given enough time, of converting one form to
another without the aid of solvent interaction (F), but they occur much more rapidly in the
presence of a solvent or solvent vapour (E). To occur without mediation, such transformations
need to be thermodynamically favoured and therefore can only result in products that are
more stable than the starting material. The fact that solvents can accelerate these transforma‐
tions is evidence of solid-solvent interaction (solvent-interactive transformation), but direct
conversion rules out mediation. In these instances the solvent or solvent vapour acts as a
catalyst to transformation by reducing the energy barrier and increasing the rate at which the
transformation occurs. This is a purely kinetic phenomenon. We therefore propose the use of
the term “solvent-catalysed transformation” for cases where a solvent or solvent vapour increases
the rate of a non-mediated transformation.
Some authors [4, 9, 10] have described solvent-mediated processes as requiring the removal
of the solvent to obtain the transformation product. We believe that this may be ascribed to a
failure to distinguish between multiple transformations. It is much more likely that solvent-
mediated transformation will have resulted in a metastable form (Form Y) that subsequently
transformed, via regular non solvent-interactive solid-solid transformation (G), to a more
stable form (Form Z). Another possibility is that said metastable form (Form Y) could have
undergone solvent-catalysed transformation to a more stable form (Form Z).
From the above discussion, the following definitions were distilled:
Solvent-interactive transformation: A solid-state transformation which is caused or accelerat‐
ed by the presence of solvent in liquid or vapour form.
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Three types of solvent-interactive transformation exist:
• Solution-mediated transformation: A solid-solution-solid transformation of the solid-state
in which no direct transformation of the starting material to the product takes place, but
which is instead mediated by a solution of the starting material in a solvent that was
introduced in liquid or vapour state.
Examples:
◦ Dissolution: metastable form transforms to stable form
Figure 1. Solvent-interactive transformations.
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◦ Recrystallisation to obtain polymorphs, hydrates and solvates
◦ Vapour sorption on the surface of the starting material resulting in deliquescence and
subsequent transformation to a hydrate/solvate or more stable polymorph
• Solvent-mediated transformation: A solid-solid transformation of the solid-state in which
no direct transformation of the starting material to the product takes place, but which is
instead mediated by an interaction between the undissolved starting material and a solvent
that was introduced in liquid or vapour state.
Examples:
◦ Anhydrous form converting to a hydrate or solvate
◦ Solvent exchange resulting in a change of structure
◦ Crystallisation of an amorphous form to a solvate or hydrate
• Solvent-catalysed transformation: A direct, non-mediated, solid-solid transformation of the
solid-state which is accelerated by the catalytic effect of a solvent introduced in liquid or
vapour state.
Example:
◦ Accelerated crystallisation of an amorphous form to an anhydrous crystalline form due to
plasticisation
With fundamental definitions now having been set, Table 2 should be reconsidered. It is now
obvious that the driving force for solvent-mediated transformation cannot be the removal of
the solvent and that any transformation subsequently taking place outside of the solvent
during drying has to be a non solvent-interactive solid-solid transformation. It is equally
obvious that solution-mediated transformation is not limited to metastable forms that convert
to more stable forms. The last two statements about solution-mediated transformation in Table
2 are perhaps not erroneous per se, but they are vague enough to warrant further discussion.
A metastable form will convert to a more stable form via solution-mediated transformation if
a saturated solution of the metastable form, supersaturated regarding the stable form, exists.
Transformation will happen through nucleation and crystal growth of the stable form. This
means that continued contact with the metastable form is only required to feed and maintain
crystal growth of the stable form. As for the transformation taking place “in solvent”, the
presence of solvent is most definitely required for a solution of the starting material to be
obtained, however the starting material needs not necessarily have been placed “in solvent”.
If solvent vapour were to adsorb onto the starting material, and said material is sufficiently
soluble in that solvent, the solid may deliquesce to create a solution layer around it in which
solution-mediated transformation could take place.
The processes and implications of solvent-interactive transformations will be discussed, with
reference to practical examples, in the following section.
Solvent-Interactive Transformations of Pharmaceutical Compounds
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4. Implications of solvent-interactive transformations
Solid-state transformations can affect a significant number of solid dosage form attributes.
Aspects like dissolution, bioavailability, stability, appearance, manufacturability, hardness, to
name but a few, can be influenced by solid-state transformations [15]. The effect of solvent-
interactive transformations on the dissolution and bioavailability of metastable drugs is of
particular concern, especially with poorly soluble drugs where a further decrease in solubility
or dissolution rate will negatively impact bioavailability and subsequent treatment outcomes
[4]. In this section the macrolide antibiotic, roxithromycin, will be used as a model drug to
illustrate the effects of solvent-interactive transformations on solid-state properties.
Studies on the physico-chemical properties of roxithromycin showed that solid-state trans‐
formations attributable to solvent interaction are possible. Solution-mediated transformation
of roxithromycin metastable forms to the thermodynamically favoured form was identified
during dissolution studies. Powder dissolution studies were done using three solid-state forms
of roxithromycin [16]. During the dissolution studies of the roxithromycin solid-state forms,
the solid-state transformation of the metastable forms to the stable monohydrate was demon‐
strated. Powder dissolution studies were done in distilled water at 25°C with a rotational speed
of 100 rpm. No medium replacement was done, because doing so will mask or suppress the
transformation. During the dissolution process a steady decline in the dissolved roxithromycin
concentration was observed after about 120 minutes for roxithromycin Form III (anhydrate).
In comparison, the transformation of the amorphous form of roxithromycin (Form II) to stable
Form I resulted in a concentration decrease after approximately 40 minutes (Figure 2).
Further studies of the solution-mediated transformation process of roxithromycin solid-state
forms were done utilising X-ray powder diffraction (XRPD) and subsequent principal
Figure 2. Dissolution profiles obtained from powder dissolution studies of different roxithromycin solid-state forms at
25°C and 100 rpm rotational speed. (Form I=roxithromycin monohydrate; Form II=amorphous roxithromycin; and
Form III=roxithromycin anhydrate).
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component analysis (PCA). During the XRPD experiments anhydrous and amorphous
roxithromycin (Form III and II, respectively) were separately exposed to a sufficient amount
of distilled water to allow dissolution, resulting in the nucleation and crystal growth of Form
I. This experiment was performed at 25°C (± 2°C). From the experimental data of the trans‐
formation process of Form III to Form I it was possible to quantify the transformation process.
This was done by following either the decrease or increase of a particular Bragg peak, char‐
acteristic to the solid-state forms under investigation. This method was investigated and
established as an accepted technique to determine phase transformations by Klug and
Alexander in 1974 [17].
The decrease of the anhydrous portion and subsequent increase of the monohydrate form
of roxithromycin is plotted versus time in Figure 3. With the help of the phase proportion
graph the investigators were able to determine the time required for Form III to complete‐
ly disappear [16].
The XRPD cluster analysis of amorphous roxithromycin is depicted in Figure 4. The plot shows
a 25% conversion from cluster 1 to cluster 23 and further cluster analysis eventually showed
a 100% conversion of Form II to stable Form I as depicted in Figure 5.
Figure 3. Phase conversion of anhydrous roxithromycin (Form III) to the stable monohydrate (Form I) at 25°C (± 2°C).
Adapted, with permission from [16].
The pharmaceutical impact of such a solid-state transformation can be significant. Currently,
the incorporation of metastable forms of drugs into solid dosage forms is at the order of the
day due to their improved dissolution and solubility properties. When considering a solution-
mediated transformation such as described above, one can see that it will lead to a decrease in
the solubility and dissolution rate of a drug, which will ultimately influence the bioavailability
negatively. At this time no reports could be found on solution-mediated transformations that
have occurred in vivo, but we could also not find any mention of it yet having been investigated
at all. In theory it could happen that the in vivo rate of dissolution of an orally administered
solid metastable form might exceed the maximum possible rate of absorption for that specific
Solvent-Interactive Transformations of Pharmaceutical Compounds
http://dx.doi.org/10.5772/59586
11
drug, resulting in a supersaturated solution that can lead to nucleation and crystal growth of
the more stable, less soluble drug within the gastro-intestinal tract.
Another theoretical possibility is that, during dissolution testing, the undissolved portion of
a metastable solid could undergo solvent-mediated and/or solvent-catalysed transformation
Figure 4. Phase conversion of amorphous roxithromycin at 25°C (± 2°C) determined with XRPD cluster analysis (PCA).                               
 
Cluster 1
Cluster 54
Cluster 23 
Figure 5. Representative XRPD patterns showing the solid-state transformation of amorphous roxithromycin (A).
(B=PCA Cluster 23: partial conversion; C=PCA Cluster 54: complete conversion to Form I).
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parallel to the solution-mediated process in which the dissolved portion is participating. To
investigate the possibility of parallel solvent-interactive transformations occurring during the
dissolution testing of metastable roxithromycin forms, vapour-sorption studies were per‐
formed. The vapour sorption isotherm given in Figure 6 shows no recrystallisation due to
solvent-interactive transformation. Had solvent-interactive crystallisation taken place, it
would have been evident from a step increase or-decrease in the weight of the sample [18] as
opposed to the observed gradual increase and decrease corresponding to relative humidity.
A step increase in the weight during crystallisation can be explained by the incorporation of
solvent molecules in the new crystal structure to form a solvate/hydrate by solvent-mediated
transformation. When a step increase is observed during sorption analysis, care should be
taken to rule out the possibility of deliquescence however, this will likely manifest as a more
drawn-out process of weight gain and the sample will become visibly wet. Deliquescence of
a sample due to the exposure to vapour might lead to a solution-mediated transformation. A
step decrease in sample weight associated with solvent-interactive transformation can be
ascribed to the fact that a form results which has a denser crystal structure, more efficient
molecular packing arrangement and fewer voids which may accommodate solvent molecules.
The transformation to a denser form therefore leads to the displacement of solvent molecules
from the solid and a resultant decrease in sample weight. A step decrease may be observed if
an anhydrous crystalline form is obtained via solvent-catalysed transformation OR if the
hydrate/solvate, produced via solvent-mediated transformation, incorporates less solvent than
the starting material can accommodate at the same humidity level.
Evaporative recrystallisation (at 25°C ± 2°C) of roxithromycin monohydrate (Form I) from
dichloromethane  (DCM)  results  in  a  roxithromycin  DCM  solvate  via  solution-mediated
transformation.  Drying of  the  DCM solvate  in  an oven at  50°C for  24  hours,  results  in
desolvation to roxithromycin anhydrate (Form III) by means of a non solvent-interactive
solid-solid transformation. The XRPD patterns of Form I,  Form III and the DCM solvate
are given in Figure 7.
Roxithromycin is also capable of a solid-state transformation through a solvent-mediated
process by means of solvent exchange. Mallet et al.  [19] reported the transformation of a
1:1  roxithromycin  acetonitrile  (ACN)  solvate  to  roxithromycin  Form  I  via  a  solid-solid
transformation  in  the  presence  of  water  vapour.  During  this  study,  well-defined  single
crystals  of  the roxithromycin ACN solvate were removed from the crystallisation medi‐
um  and  maintained  at  100%  relative  humidity  (RH)  and  ambient  temperature.  The
investigators  observed  that  the  initially  clear  crystals  became  opaque  after  48  hours
however, the shape of the crystals remained unchanged. Subsequent analysis of the opaque
crystals showed that the acetonitrile molecules had been replaced by water, resulting in a
stoichiometry of 1:1 (roxithromycin : water). One might argue that the transition could also
have been due to a solution-mediated process since an environment of 100% RH could have
led to deliquescence of the crystals and resultant dissolution and recrystallisation. Further
studies  by  Aucamp  [20]  however,  showed  that  the  same  transformation  will  occur  at
ambient conditions. The study showed that, upon storage of the acetonitrile solvate crystals
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at  ambient  conditions  (25°C  /  65%  RH),  the  same  transformation  occurs,  resulting  in
roxithromycin : water (1:1) stoichiometry.
Figure 6. Moisture sorption isotherms of amorphous roxithromycin. Adapted, with permission, from [16].
Considering the fact that it can be challenging to determine whether any given solvent-
interactive transformation is occurring in isolation, in parallel with others, or even as part of
a number of transformation steps, care should be taken when interpreting experimental
observations and, where possible, multiple techniques should be used to verify results.
5. Solid-state transformations and pharmaceutical manufacturing
The previous sections focused on neat APIs and transformations that occur during pre-
formulation steps. However, it should be mentioned that the combination of drugs with
excipients might also lead to significant phase changes. Tablets and capsules contain drugs
and excipients and are formulated in such a manner that enhanced performance and physical
appearance will be obtained. Even if the physico-chemical properties of the drug are taken into
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account and compensated for, the excipients included in the formulation, as well as, the
manufacturing steps taken, can still cause unforeseen solid-state transformations of the drug.
It cannot be emphasised enough that, after an in-depth physico-chemical study of the drug,
the next step should be to investigate the effects that excipients and processing of the drug in
combination with excipients will have on the solid-state properties of the drug. Excipients may
facilitate conversion of an amorphous form to a crystalline form or vice versa. Hydration or
dehydration of a drug might be triggered by an excipient, which might lead to the formation
of metastable or stable forms or mixtures of various crystalline forms of a given drug. All of
(a) 
(b) 
(c) 
Figure 7. XRPD patterns of (a) roxithromycin monohydrate (Form I), (b) a roxithromycin DCM solvate and (c) roxi‐
thromycin anhydrate (Form III). Single crystal structural data of roxithromycin Form I (monohydrate) is available from
the Cambridge Structural Database (reference code: FMPROA) [19].
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these solid-state changes can have detrimental effects on the product stability and ultimately
the treatment of patients.
A multitude of processes are employed during the manufacturing of solid dosage forms
(Figure 8). Although some of these methods do not involve the use of solvents, it should be
realised that these methods can alter the solid-state of the drug and this altered state might be
prone to solvent-interactive transformations at a later stage.
Generally, the first step during the manufacturing of a solid dosage form is size reduction of
the drug particles. Size reduction is necessary to improve morphological characteristics,
powder flow properties and uniformity. Size reduction is usually achieved through milling [4].
Milling or grinding imparts mechanical stress and often generates heat that might cause
dehydration or complete/partial vitrification of the drug. If the intactness of the preferred solid-
state is not confirmed at this stage, any undetected solid-state transformation will be prob‐
lematic during ensuing stages of manufacturing or during after-production quality testing.
Therefore, because milling can cause solid-solid transformations it is imperative to understand
that incorporation of a drug, with an already altered state, into a product will most probably
lead to solvent-interactive transformations during other stages of the production cycle.
Granulation is often the next processing step to which a drug is subjected. During this step,
the combination of the drug with some or other excipients come into play. Granulation is a
processing step that is employed to improve flowability, cohesiveness, compressibility and/or
lubrication of the bulk material. There are very few APIs that do not need improvement in
terms of flowability or compressibility and therefore a substantial percentage of drugs are
granulated before further formulation steps towards tablet/capsule production. Two types of
granulation are commonly used in industry, namely: wet granulation and dry granulation.
Wet granulation is the most widely used due to its versatility and superior results in terms of
bulk properties. Even though wet granulation is usually the preferred method for granulation
it is also the most likely to induce solid-state transformations. The liquid used during the
granulation process, drying parameters, drug loading, solubility of the drug in the granulation
fluid and the procedure for including the drug into the granules are all factors that may affect
the solid-state form of the drug. Wet granulation creates favourable conditions for solvent-
interactive transformations to occur, often resulting in hydration/solvation, polymorphic
conversions, vitrification or crystallisation [4].
In solid dosage form manufacturing, the use of dry granulation is reserved for drugs that are
sensitive to moisture and/or elevated temperatures, because it requires neither solvents for
granulation nor heat for drying. The mechanical stresses imparted on the drug through the
dry granulation process can lead to solid-solid transformations that ultimately might lead to
solvent-interactive transformation further along the manufacturing process. For both wet-and
dry granulation, mixing with excipients might also induce solid-state transformations due to
incompatibility reactions that might occur.
Spray-drying is a technique that produces homogenous particles of uniform shape and size.
This process requires the complete or partial dissolution of the drug in a solvent and therefore
increases the probability of solid-state changes due to solvent-interactive transformation.
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Figure 8. Flow diagram illustrating the processing steps for a pharmaceutical product, to obtain a solid dosage form,
indicating where solvent-interactive transformations can occur.
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Solvent removal from the spray of droplets is a rapid process that may lead to crystallisation
of a metastable form or even another polymorphic form [4, 21].
After powder characteristics have been improved, a second granulation or blending step
usually follows. This processing step is generally considered a low energy and- intensity step
and is unlikely to induce solid-state changes, although it should not be completely excluded
as a possibility. Also, the fact that the drug is now being mixed with lubricants, glidants and
disintegrants makes the detection of phase changes more difficult. Tablet compression is
another high energy process that can induce solid-solid transformations to metastable forms.
Following compression of the drug-excipient blends, a coating process may be required or
desired. In most cases it is unlikely that a solid-state change will occur during film-coating due
to the fact that process parameters have been optimised to such an extent that the period of
time for which the tablet is subjected to the coating solution is minimal. Drying of the coating
by means of an efficient air exchange method also ensures a short exposure time of the tablet
to the coating solution [4]. On the other hand, coating procedures used in the manufacture of
modified release products may cause problems. Generally, in the case of modified release
products, a portion of the total dose may be applied as a drug coating layer. This coat is essential
in providing immediate release for fast onset of action. Typically, the drug layer is applied by
spraying a drug-excipient solution or suspension onto the tablet surface. Dissolving or
suspending the drug in a liquid significantly increases the probability of solvent-interactive
transformations occurring. Furthermore, the rapid solvent removal after the coating process
could lead to the precipitation of an altered solid-state form in the coating layer [4].
Considering all the pitfalls and challenges mentioned above, it becomes clear that solid-state
transformations and the prevention thereof are of critical importance to the pharmaceutical
industry. Not only must the pharmaceutical scientist keep a watchful eye out for solvent-
interactive transformations occurring during the manufacturing of neat drugs, but attention
must also be paid to solid-solid transformations arising during final product manufacturing.
6. Regulatory requirements: Solid-state characterisation and monitoring
According to the Food and Drug Administration’s (FDA’s) guideline on drug substances it is
a regulatory requirement that the solid-state form of a drug be controlled throughout all
processing and manufacturing steps. It is also required that the solid-state form of a drug must
be known at any given time during the product manufacturing process, as well as during
storage and distribution. Guidelines established by the International Conference for Harmo‐
nization (ICH) require a complete polymorphic study of a new drug prior to the product
development stage [1, 4, 22].
Nearly a decade ago, a regulatory framework, namely Process Analytical Technology (PAT),
was established. This FDA initiative encompasses the following:
1. To ensure product quality and performance through the design of effective and efficient
manufacturing processes;
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2. Specifications of products and processes are based on a mechanistic understanding of how
processing steps and formulation can affect product performance;
3. Continuous and real-time quality assurance of the pharmaceutical compound;
4. Risk-based regulatory approaches to understand how formulation and manufacturing
processes can affect the quality and performance of the end-product; and
5. The establishment of process control strategies to prevent or mitigate the risk of having a
poor quality product at the end of a manufacturing process.
PAT was developed to ultimately build quality into pharmaceutical products. The guide
highlights the necessity for understanding processes that could detrimentally affect pharma‐
ceutical products [22, 23]. It is not only thorough initial characterisation (and the reporting of
knowledge gained) that is essential, but also the continuous monitoring of pharmaceutical
ingredients during the manufacturing of medicines. In essence, this guide states that the solid-
state form used to produce a dosage form must be known, as well the effects of solid-state
changes on the performance or stability of the drug product. The influence that solvent-
interactive transformations can have on the solid-state properties of a drug was discussed in
detail in the previous sections of this chapter.
Numerous analytical techniques are available for the rigorous characterisation and monitoring
of solid-state forms of APIs. To avoid oversights and inconclusive results, it is always advisable
to use multiple complimentary techniques. Advances made in the refinement of techniques,
and the improvement of equipment sensitivity, allow for better characterisation of not only
new chemical entities (NCEs), but also older ones for which comprehensive data was not
previously available. The “re-discovery” of older drugs is important and opens up many
opportunities for the development of optimised products with improved patient treatment
outcomes.
7. Characterisation techniques
Many analytical techniques are used to study and characterise the solid-state forms of APIs.
The following paragraphs will elaborate on the techniques and the valuable information that
can be obtained from the resulting data. Rather than defining the techniques or explaining in
detail the underlying principles on which they are based – information that is widely available
– we will focus on their application within the context of solid-state transformations.
7.1. X-Ray Powder Diffraction (XRPD)
XRPD is used to generate X-ray diffraction patterns that are unique to a specific crystalline
arrangement of a particular drug. This may serve as an identification method for specific
polymorphs. Any change in crystal structure will result in changes in the peak positions of the
diffraction pattern. XRPD may also be used to quantify the relative proportions of two forms
during a transformation process by monitoring changes in relative peak intensity, of peaks
unique to each of the two forms, over time. If an X-ray diffractometer is equipped with a
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controlled temperature-and humidity-chamber, transformations due to temperature or
moisture changes can be studied [24].
An amorphous material gives a diffraction “pattern” that lacks peaks, but instead features
broad humps, referred to as an amorphous halo [23]. Crystallisation of an amorphous material
can be confirmed if peaks appear on the diffraction pattern. The amorphous halo is not
meaningless or devoid of information, but is the result of the short-range order within the
material. If an amorphous halo is recorded with a high-energy X-ray source, and pair-
distribution-function analyses are performed, the extent of short-range order can be deter‐
mined and sometimes even “matched” to the most similar crystalline polymorph [25].
7.2. Differential Scanning Calorimetry (DSC)
This thermal method measures the amount of energy taken up or released by a sample during
a heating and/or cooling program. Thermal events such as melting, glass transition, desolva‐
tion and crystallisation are recorded on a thermogram showing heat flow against temperature
or time. Any given solid-state form of a drug will have thermal events that are characteristic
for that particular form. Changes in the number or nature of thermal events are indicative of
changes in the solid-state, as are changes in the temperature at which melting of crystalline
materials occur. Integration of the area under the heat flow curve yields the enthalpy change
associated with that particular thermal event. Although DSC analysis is not a direct method
for quantifying solid-state changes due to solvent-interactive transformations, it is still a
helpful tool to identify whether changes did occur and to what extent solid-state characteristics
were affected [4, 23].
7.3. Thermogravimetric Analysis (TGA)
TGA is a thermal technique that measures sample mass change under either isothermal
conditions or ramped heating at a set rate [26, 27]. Weight loss at temperatures lower than the
melting point of the drug is usually due to the loss of solvent. Adsorbed/absorbed moisture
or solvent vapour is usually lost gradually, whilst solvent included in the crystal structure is
typically lost in a characteristic step-wise manner. Weight loss profiles can be analysed to
determine the amount or percentage of weight lost at any given temperature [26]. By factoring
in the respective molecular weights of the drug and the lost solvent, one can also determine
the stoichiometric relationship.
7.4. Hot Stage Microscopy (HSM)
This is one of the simplest and oldest thermal analysis methods. It is used to study solid-state
transformations by observing a sample as it is heated and cooled. HSM is used to visually
confirm DSC findings and to identify thermal events that cannot be conclusively identified
from DSC thermograms. Possible observations include morphology, birefringence (polarising
filter required), solid-solid transformations, interaction between different compounds,
dissolution of one compound in another, sublimation and/or evaporation, vapour deposition,
melting/liquefaction, crystallisation/solidification, charring/decomposition, crystal growth
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and rate thereof. Gas evolution during desolvation can be observed if a sample is covered in
a drop of mineral oil [28].
7.5. Vibrational spectroscopy and microscopy
The most prominent vibrational spectroscopic methods for solid-state form identification are
infrared-(IR) and Raman spectroscopy. These two techniques can be used as qualitative and
quantitative analytical methods. Although these techniques are generally used as complimen‐
tary methods they are still important, especially for investigating differences in hydrogen-
bonding patterns that often differ with solid-state forms [8, 29]. An IR or Raman spectrum
consists of several absorption bands, each band is related to a specific vibrational or rotational
frequency. These frequencies are dependent on the intermolecular interactions and bond
strength. Therefore, the obtained ‘pattern’ due to the vibrational frequencies is highly charac‐
teristic of a given drug. Any changes in the spectra due to solid-state transformations will be
identifiable through changes in the relative intensities, frequencies, number and contours of
the absorbance bands [24]. Confocal Raman microscopy can be used for the identification of a
particular solid-state form of a drug in solid dosage forms. Not only is this a useful application
for determining drug homogeneity in the dosage form, but the identification of solid-state
transformations is also possible. Raman microscopy furthermore allows the investigation of
amorphous-to-crystalline transformation at the dissolving interface of a solid dosage form [30].
7.6. Dissolution studies
In vitro dissolution studies are extremely useful for the identification and even quantification
of solvent-interactive transformations. As mentioned earlier, the incorporation of metastable
solid-state forms in solid dosage forms, especially amorphous forms, has become increasingly
prevalent over the last decade. However, it has been demonstrated that general methods for
testing dissolution and equilibrium solubility are not optimised for determining the true
solubility advantage that these metastable forms offer [31].
Solution-mediated transformation, occurring during dissolution, involves three stages: (1) a
pre-transformation stage, during which the metastable phase dissolves at a constant rate; (2)
the transformation stage that begins after the solution has become supersaturated with respect
to the stable form. During this stage the nucleation and crystal growth of the stable form, as
well as dissolution of both forms occur. The relative amount of the stable form increases and
as a result thereof the overall dissolution rate decreases until no metastable form is left. After
the transformation stage, a steady-state stage (3) is reached (Figure 9) [32]. Aaltonen et al. [32]
reported a Raman spectroscopy method that is ideal for accurately determining drug concen‐
tration in solution as well as the concomitant analysis of the solid phase within the dissolution
environment.
7.7. Microcalorimetry
Microcalorimetry is a technique that has a variety of applications in the pharmaceutical
research environment. This technique involves the real-time monitoring of chemical and
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physical processes occurring when a compound is subjected to certain conditions (tempera‐
ture, humidity, solvent vapour or in combination with another compound). The monitoring
process can extend over a period of hours or days and it measures the onset, rate, extent and
energetics of reactions or transformations. During microcalorimetric analysis, the heat flow of
a sample is measured and recorded versus elapsed time. This analytical tool was developed
around the basic principle that all chemical and physical processes are either exothermic or
endothermic. Microcalorimetry is such a sensitive method that it can detect very slow proc‐
esses. It will also detect physical or chemical reactions that generate minuscule amounts of
heat. To study solid-state transformations due to solvent vapour exposure, a small amount of
drug will be added to an inert ampoule and a micro hygrostat filled with the solvent will be
inserted into the ampoule [33]. A specific humidity environment can also be created within
the sealed ampoule by using a micro hygrostat containing saturated salt solutions and
maintaining the calorimeter at a specific temperature. Any solid-state transformation will be
seen as either an increase or decrease in the measured heat flow. The heat flow data can be
applied to calculate the kinetics of a transformation process.
7.8. Vapour sorption analysis
Vapour sorption analysis, also known as dynamic vapour sorption (DVS), is a gravimetric
technique that measures the amount and rate of solvent absorption/adsorption by a sample.
Typically, water sorption-desorption isotherms are obtained by exposing a sample to a relative
humidity (RH) cycle ranging from 0 – 98% and plotting the corresponding weight change.
During typical vapour sorption studies the temperature is kept constant at 25°C ± 0.5°C,
however some sorption analysers have the ability to apply a temperature ramp as well.
Figure 9. Typical dissolution graph showing the effect on concentration of solution-mediated solid-state transforma‐
tion of a metastable drug to a stable form of the drug.
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Sorption analyses usually involves 3 steps, namely a first up-ramping of the RH (0 to 98%),
secondly a downwards ramp of the RH (98 to 0%) and thirdly and finally another upward
ramping (0 to 98%). These RH ramping steps are usually applied when one wants to study the
effect that water has on a drug during high % RH conditions. The resulting moisture sorption
and desorption isotherms will indicate any change in the sample weight during the humidity
ramps. Differences in the adsorption and desorption isotherms is referred to as hysteresis.
The solid-state change of an amorphous drug can be detected through sorption analysis. The
glass transition is the point where an amorphous material becomes less stable and rearrange‐
ment to the more stable crystalline structure occurs. Typically the glass transition is affected
by temperature and humidity. Hence, it can be determined using either ramped temperature
experiments at constant humidity or using ramped humidity experiments at constant tem‐
perature. The amorphous material gains weight until the glass transition is reached. Then, as
the amorphous drug rearranges to the crystalline form, there is a step increase or decrease in
weight [18]. Another occurrence that can easily be identified from vapour sorption studies is
that of deliquescence. Drugs that are susceptible to deliquescence will absorb very little
moisture during a humidity ramp until the % RH reaches a “critical” level. At that point the
drug will absorb any available moisture. This will result in a rapid increase of the monitored
sample weight [34]. It should be noted that, if possible, vapour sorption studies should be
performed in conjunction with XRPD, DSC and/or TG analyses. This will assist in the definitive
identification of solid-state changes due to exposure of the drug to vapour.
8. Conclusion
Pharmaceutical compounds have the ability to exist in different solid-state forms. The re-
arrangement of molecules, that allows a single drug to present itself in various solid-state
forms, presents an array of challenges to scientists working in the pharmaceutical industry.
Different solid-state forms of the same API differ in terms of physical, chemical and mechanical
properties. The understanding of the solid-state properties of APIs is imperative and even
more so the factors that can induce changes in the solid-state of a given drug.
This chapter focussed on the solid-state form changes that may occur due to solvent-interactive
transformations. There is much confusion and contradiction in current literature when it comes
to differentiating the types of solvent-interactive transformations. We have concluded that
solvent-interactive transformations may be either indirect and mediated or direct and non-
mediated. The latter is a solvent-catalysed solid-solid transformation, whilst the former can be
either a solvent-mediated solid-solid transformation or a solution-mediated solid-solution-
solid transformation.
Solvent-interactive transformations can affect not only drugs but also excipients used in the
formulation of a drug into a dosage form. It is essential to identify possible pitfalls, caused by
solvent-interactive transformations, during the complete drug processing and dosage form
manufacturing cycle. It is important to know that solvent-interactive transformations can
change the solid-state form of a drug at any point between the very start of manufacturing
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right up to the time when the drug is absorbed in vivo after having been administered to apatient.
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